Xu, Hengyi
Yao, Jun
Wu, Douglas C.
Lambowitz, Alan M.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM37949, GM37949, GM37949, GM37949)
Welch Foundation (F-1607, F-1607)
Article History
Received: 8 January 2019
Accepted: 17 May 2019
First Online: 28 May 2019
Competing Interests
: Thermostable group II intron reverse transcriptases (TGIRT) enzymes and methods for their use are the subject of patents and patent applications that have been licensed by the University of Texas and East Tennessee State University to InGex, LLC. A.M.L. and the University of Texas are minority equity holders in InGex and some former Lambowitz laboratory members receive royalty payments from sales of TGIRT enzymes and licensing of intellectual property.